Annovis Bio (FRA:07X) Insider Ownership: 0.00 % (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:07X Annovis Bio Inc FRA:07X
36 GF Score
Price €1.04
! 1 Warning Sign
View Full Analysis

What is Annovis Bio Insider Ownership?

Annovis Bio FRA:07X +1.93% 36 Insider Ownership is 0.00 % as of Sep. 22, 2026. GuruFocus rates FRA:07X with a GF Score™ of 36/100. The stock has 1 warning sign investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Annovis Bio's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Annovis Bio's Institutional Ownership is 7.89%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Annovis Bio's Float Percentage Of Total Shares Outstanding is 90.96%.

Annovis Bio Insider Ownership Historical Data

* Premium members only.

The historical data trend for Annovis Bio's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annovis Bio Insider Ownership Chart

Annovis Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only - - - - -

Annovis Bio Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
FRA:07X
36GF Score
Annovis Bio Inc FRA:07X
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annovis Bio Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Annovis Bio (FRA:07X) has a Insider Ownership of 0.00 % as of Sep. 22, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Annovis Bio and its competitors.
Is Annovis Bio's Insider Ownership too high?
Annovis Bio's current Insider Ownership is 0.00 %. Overall, Annovis Bio has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's Insider Ownership compare to CRDF and ELTX?
Annovis Bio's Insider Ownership of 0.00 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Annovis Bio and its competitors. Annovis Bio's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current Insider Ownership of 0.00 %. The current Insider Ownership is 0.00 %. Annovis Bio's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current Insider Ownership is 0.00 % as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annovis Bio Business Description

Other Exchanges ANVS:USA
Address 101 Lindenwood Drive, Suite 225, Malvern, PA, USA, 19355
Annovis Bio Inc. is a clinical-stage pharmaceutical company based in the United States that develops small-molecule drug candidates for neurodegenerative diseases. Its lead candidate, buntanetap, is an orally administered compound designed to inhibit the production of multiple neurotoxic proteins, including amyloid beta, tau, and alpha-synuclein, and has been studied in clinical trials for Alzheimer's disease, Parkinson's disease, and related neurodegenerative conditions. The company's pipeline also includes earlier-stage programs such as ANVS405, being explored for traumatic brain injury and stroke, and ANVS301, targeting cognitive decline in advanced Alzheimer's disease and dementia. As a clinical-stage company, Annovis Bio does not yet generate product revenue; it funds operations primarily through equity financings, grants, and partnerships, and its activities are concentrated in the U.S. research and clinical development market.
36GF Score

Get the complete analysis for FRA:07X

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.04
Price